Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer.

M. G. Daidone, R. Silvestrini

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

In breast cancer, proliferative activity represents one of the biologic processes most thoroughly investigated for its association with tumor progression. In addition to the mitotic activity component of pathologic grading systems, several proliferation indices have provided independent information on prognosis and response to specific treatments in large retrospective studies. Recently, results from treatment protocols prospectively planned to test the clinical utility of proliferative activity have indicated that tumor cell proliferation markers identify two subsets among patients with lymph node-negative cancers: 1) those at a very low risk of relapse and 2) those who will benefit from regimens including antimetabolites. Future efforts should compare the prognostic accuracy of different proliferation markers, confirm preliminary evidence of a relationship between proliferation and response to specific systemic treatments, and standardize assay techniques to facilitate their transfer to general oncology practice.

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalJournal of the National Cancer Institute - Monographs
Issue number30
Publication statusPublished - 2001

Fingerprint

Breast Neoplasms
Antimetabolites
Neoplasms
Clinical Protocols
General Practice
Therapeutics
Retrospective Studies
Lymph Nodes
Cell Proliferation
Recurrence

Cite this

@article{b286a20e8eab4855883749652f16785a,
title = "Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer.",
abstract = "In breast cancer, proliferative activity represents one of the biologic processes most thoroughly investigated for its association with tumor progression. In addition to the mitotic activity component of pathologic grading systems, several proliferation indices have provided independent information on prognosis and response to specific treatments in large retrospective studies. Recently, results from treatment protocols prospectively planned to test the clinical utility of proliferative activity have indicated that tumor cell proliferation markers identify two subsets among patients with lymph node-negative cancers: 1) those at a very low risk of relapse and 2) those who will benefit from regimens including antimetabolites. Future efforts should compare the prognostic accuracy of different proliferation markers, confirm preliminary evidence of a relationship between proliferation and response to specific systemic treatments, and standardize assay techniques to facilitate their transfer to general oncology practice.",
author = "Daidone, {M. G.} and R. Silvestrini",
year = "2001",
language = "English",
pages = "27--35",
journal = "Journal of the National Cancer Institute. Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "30",

}

TY - JOUR

T1 - Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer.

AU - Daidone, M. G.

AU - Silvestrini, R.

PY - 2001

Y1 - 2001

N2 - In breast cancer, proliferative activity represents one of the biologic processes most thoroughly investigated for its association with tumor progression. In addition to the mitotic activity component of pathologic grading systems, several proliferation indices have provided independent information on prognosis and response to specific treatments in large retrospective studies. Recently, results from treatment protocols prospectively planned to test the clinical utility of proliferative activity have indicated that tumor cell proliferation markers identify two subsets among patients with lymph node-negative cancers: 1) those at a very low risk of relapse and 2) those who will benefit from regimens including antimetabolites. Future efforts should compare the prognostic accuracy of different proliferation markers, confirm preliminary evidence of a relationship between proliferation and response to specific systemic treatments, and standardize assay techniques to facilitate their transfer to general oncology practice.

AB - In breast cancer, proliferative activity represents one of the biologic processes most thoroughly investigated for its association with tumor progression. In addition to the mitotic activity component of pathologic grading systems, several proliferation indices have provided independent information on prognosis and response to specific treatments in large retrospective studies. Recently, results from treatment protocols prospectively planned to test the clinical utility of proliferative activity have indicated that tumor cell proliferation markers identify two subsets among patients with lymph node-negative cancers: 1) those at a very low risk of relapse and 2) those who will benefit from regimens including antimetabolites. Future efforts should compare the prognostic accuracy of different proliferation markers, confirm preliminary evidence of a relationship between proliferation and response to specific systemic treatments, and standardize assay techniques to facilitate their transfer to general oncology practice.

UR - http://www.scopus.com/inward/record.url?scp=0035755626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035755626&partnerID=8YFLogxK

M3 - Article

SP - 27

EP - 35

JO - Journal of the National Cancer Institute. Monographs

JF - Journal of the National Cancer Institute. Monographs

SN - 1052-6773

IS - 30

ER -